Vulinacimab
Product Specifications
CAS Number
2250342-36-8
Target
VEGFR
Related Pathways
Tyrosine Kinase/Adaptors|||Angiogenesis
Bioactivity
Vulinacimab (HLX-06), an anti-VEGFR-2 monoclonal antibody (mAb), plays a pivotal role in cancer research due to VEGFR-2's significant involvement in angiogenesis, as well as the proliferation, survival, migration, and differentiation of endothelial cells, processes critical for tumor growth where VEGFR-2 is overexpressed [1].
Shipping Conditions
Cool pack
Storage Temperature
-20°C
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
T9161-22R 100 µg
Tumor Necrosis Factor Receptor 2, p75/p80 (TNFR 2, TNFR2, TNF-R2, Tumor Necrosis Factor Receptor Type II, TNFR-II, TNF-RII, TNF-R-II, CD120b, Etanercept, p75, p75TNFR, p80 TNF alpha Receptor, TNF-R75, TNFR80, Tumor Necrosis Factor beta Receptor, TNFBR, TBPII, Tumor Necrosis Factor Receptor Superfamily Member 1B, TNFRSF1B, TNFR1B)
Ask
View Details 